Editorials

Rare diseases in general practice: recognising the zebras among the horses

“When you hear hoofbeats, don’t expect to see a Zebra.”

The above adage is especially useful in primary care as many of the conditions we see are common. But it is not so useful when we consider our role in both diagnosing and supporting patients with rare diseases. We must be ready to think again and look out for the horse with stripes.

A rare disease is defined by an incidence of <5 cases per 10 000 population, however the vast majority of the 7000 rare diseases are far less common.

Eighty per cent of rare diseases have a genetic basis, and genomic research has led to the determination of diseases that may be affected before diagnosis, it informs the patient and family in gaining access to social and educational support.

So what role does general practice have in rare disease diagnosis? Where there is suspicion, an accurate three-generation family history may provide clues of an inherited disease. A review of the key features can form the basis of a problem-based search for differential diagnoses utilising web-based resources (for example, www.findzebra.com/; www.omim.org/; www.orpha.net/censor/cgi-bin/index.php; and phenomizer-orphanet: http://compbio.charite.de/phenomizer_orphanet/).

The differential diagnoses generated will then inform subsequent investigation and referral, advice is normally readily available from clinical genetic departments or, if an inborn error of metabolism is considered, regional specialist metabolic laboratories.

A GP CAN UNIQUELY HELP

Of course it is unrealistic to expect anyone to know all 7000 rare diseases, or for a GP to make an immediate spot diagnosis the moment a patient walks in. But GPs are in a unique position. We offer whole patient and family care with continuity of clinical record over many years. We are used to managing diagnostic uncertainty, excluding serious pathology and to consider diagnoses that we may only see a handful of times in our career, for example, infectious diseases such as meningococcal sepsis and certain cancers. By keeping an open mind we have the tools and ability to ‘join the dots’, identify unusual patterns of disease and revisit diagnoses.

Patients with a rare disease typically seek an empowering and collaborative approach with their clinicians. They and their carers are often ‘expert patients’, which can challenge the traditional patient–doctor relationship, shifting the usual knowledge asymmetry. By acknowledging each other’s mutual skills and expertise an effective and rewarding partnership can be achieved.

CARING FOR PATIENTS WITH RARE DISEASES IN PRIMARY CARE

After a long diagnostic journey, the relief of diagnosis is often short-lived as patients come up against the frustrations associated with orphan diseases: a lack of information, treatments and variability in the level and coordination of care. For some diseases national or regional-specialised centres are in place and make a huge difference, but this may be at the detriment of local

Box 1. Niemann–Pick disease, type C: a highly variable rare disease

Niemann–Pick disease, type C (NPC) is a lysosomal storage disorder, historically considered an aggressive neurodegenerative disease of children, with death typically in their teenage years. There is now much wider recognition that the largest subgroup is undiagnosed, with a less aggressive phenotype, presenting later with insidious onset dementia, ataxia, and frequently, psychosis.

prognosis and importantly, it assists the patient and family in gaining access to social and educational support.

Patients with a rare disease typically seek an empowering and collaborative approach with their clinicians. They and their carers are often ‘expert patients’, which can challenge the traditional patient–doctor relationship, shifting the usual knowledge asymmetry. By acknowledging each other’s mutual skills and expertise an effective and rewarding partnership can be achieved.

Box 2. The newborn blood spot test

This now includes 9 tests (including 6 inherited metabolic conditions)

• Sickle cell disease
• Cystic Fibrosis
• Congenital hypothyroidism
• Phenylketonuria (PKU)
• Medium-chain acyl-CoA dehydrogenase deficiency (MCADD)

Since 2015:

• Maple syrup urine disease (MSUD)
• Isovaleric acidemia (IVA)
• Glutaric aciduria type 1 (GA1)
• Homocystinuria (HCU)
knowledge of the patient and their disease. A GP can help fill this void. Through increasing familiarity of the disease and how it impacts the patient and their family we can help navigate and coordinate local hospital specialties and other agencies’ involvement.

Simple things can also help. Patients with rare diseases often report frustration that they need to explain their disease to every clinician they meet. Prominently-placed disease summaries, relevant letters and care plans are all easy ways to help ensure familiarity among the health professionals patients may encounter.

Good holistic care for the patient and their family is invaluable for what are often devastating, life-limiting illnesses. It is important to avoid the trap of attributing every ailment to the ‘headline’ disease, overlooking easily-treatable problems. For example, recognising and treating constipation or depression in patients with complex neurological diseases not only has a profound effect on their well-being but even the apparent disease severity.

THE FUTURE OF RARE DISEASES IN PRIMARY CARE
In 2013 the UK Strategy for Rare Disease highlighted the need for better coordination of care, the empowerment of patients, better diagnostics, and earlier diagnosis interventions. It also highlighted the integral, yet difficult role that GPs have, especially in the diagnosis of rare diseases. The UK Rare Disease Forum has recently produced a report assessing the progress made toward the 51 published recommendations. The report acknowledges the progress made in molecular diagnostics, including the 100 000 genome project, the expansion of the newborn screening programme in 2015 and the unexpected results. Will we, in primary care, be responsible for conveying this information and if so, how will we do it? Additional rare diseases will continue to be described and common diseases broken into molecularly-defined subtypes, each with targeted therapies. We will need to utilise this knowledge to ensure that the best treatments are given to patients but also at a sustainable cost. Defining what is cost-effective will continue to be a contentious question for society, and a difficult challenge for national commissioners of rare disease services.


Imran Rafi, Chair of RGCP Clinical Innovation and Research, Royal College of General Practitioners, 36 Euston Square, London.

Provenance Commissioned; not externally peer reviewed.

Competing interests William Evans is a Trustee of Niemann-Pick UK and Imran Rafi is a Member of the UK Rare Disease Forum and the UK Rare Disease Advisory Group.

DOI: 10.3399/bjgp16X687625

REFERENCES